Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Androgen”

204 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 204 results

Very early researchStudy completedNCT03004534
What this trial is testing

Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide

Who this might be right for
Breast Cancer Female
Translational Research in Oncology 36
Very early researchStudy completedNCT03507608
What this trial is testing

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03090165
What this trial is testing

Ribociclib and Bicalutamide in AR+ TNBC

Who this might be right for
Triple Negative Breast Cancer
Kari Wisinski 37
Testing effectiveness (Phase 2)Study completedNCT05694819
What this trial is testing

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Who this might be right for
Salivary Gland Cancer
National Cancer Center Hospital East 57
Testing effectiveness (Phase 2)Looking for participantsNCT05891795
What this trial is testing

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

Who this might be right for
Acne Vulgaris
Stanford University 18
Early research (Phase 1)Ended earlyNCT05241613
What this trial is testing

AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Accutar Biotechnology Inc 28
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT01393730
What this trial is testing

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Mary-Ellen Taplin, MD 40
Testing effectiveness (Phase 2)Study completedNCT01867333
What this trial is testing

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Study completedNCT00468715
What this trial is testing

Bicalutamide in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT01942837
What this trial is testing

Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute 67
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Testing effectiveness (Phase 2)Study completedNCT02697032
What this trial is testing

FDHT PET and Bicalutamide in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University Medical Center Groningen 22
Testing effectiveness (Phase 2)UnknownNCT06108193
What this trial is testing

Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris

Who this might be right for
Acne Vulgaris
Chang Gung Memorial Hospital 26
Not applicableUnknownNCT01852786
What this trial is testing

The Effect of Hormonal Contraception on Female

Who this might be right for
Adverse Effect of Oral Contraceptives, Initial Encounter
Lithuanian University of Health Sciences 340
Early research (Phase 1)Ended earlyNCT04279561
What this trial is testing

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8+2 more
Jonsson Comprehensive Cancer Center 9
Early research (Phase 1)UnknownNCT01239888
What this trial is testing

Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study

Who this might be right for
DepressionMajor Depressive Disorder
The Alfred 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02749903
What this trial is testing

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Who this might be right for
Salivary Cancer
Alliance for Clinical Trials in Oncology 46
Early research (Phase 1)Study completedNCT01696604
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects

Who this might be right for
Cachexia
GlaxoSmithKline 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT02949284
What this trial is testing

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Who this might be right for
Stage II Prostate AdenocarcinomaStage III Prostate Adenocarcinoma
Rutgers, The State University of New Jersey 90
Load More Results